Posts in category Access to Affordable Medicines
Access to Affordable MedicinesAddiction, Depression, Psychosis, SchizophreniaBusinessDigital HealthEpidemics & PandemicsHealthcare PoliticsHealthcare Privatization: A Global Business Campaign
Medicare’s Public-Private Virtualization (The Logic, Nov 27 2021)
For Telus CEO Darren Entwistle, virtual health is personal – The Logic
Access to Affordable MedicinesAntibiotic ResistanceCanadian Science PolicyDiseases of NeglectDrug PoliticsEpidemics & PandemicsGlobal HealthHealthcare PoliticsInternational DevelopmentScience
Nature Medicine: Biomedical research during the COVID lockdown
Government-funded medical research bodies in the UK, Europe, USA and Australia say they are committed to maintaining funding continuity for biomedical research. So far, only in Canada has a major …
Access to Affordable MedicinesAddiction, Depression, Psychosis, SchizophreniaBusinessDrug PoliticsHealthcare Politics
Psychedelic therapies?
Lancet May 19 2019 Psychedelic therapy
Access to Affordable MedicinesAddiction, Depression, Psychosis, SchizophreniaDrug PoliticsHealthcare Politics
Canada’s expanding cannabis market sparks worries
Lancet Jan 12 2019 Canada’s expanding cannabis market
New Drugs for Psychosis & Schizophrenia
The Lancet May 5 2018 FDA Pimavanserin review
Access to Affordable MedicinesAddiction, Depression, Psychosis, SchizophreniaDrug PoliticsHealthcare PoliticsHealthcare Privatization: A Global Business Campaign
Canada considers fairer pharma prices
Spending by Canadian governments on patented drugs costing more than $10 000 per patient annually increased 60% in 2016 . Spending on brand-name pharmaceuticals as a whole rose 18%.